Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
A Global, Regional, and National Survey on Burden and Quality of Care Index (Qci) of Hematologic Malignancies; Global Burden of Disease Systematic Analysis 1990–2017 Publisher



Keykhaei M1 ; Masinaei M1, 2 ; Mohammadi E1 ; Azadnajafabad S1 ; Rezaei N1, 7 ; Saeedi Moghaddam S1 ; Rezaei N1, 7 ; Nasserinejad M1, 3 ; Abbasikangevari M1, 4 ; Malekpour MR1 ; Ghamari SH1, 4 ; Haghshenas R1, 7 ; Koliji K5 ; Kompani F6 Show All Authors
Authors
  1. Keykhaei M1
  2. Masinaei M1, 2
  3. Mohammadi E1
  4. Azadnajafabad S1
  5. Rezaei N1, 7
  6. Saeedi Moghaddam S1
  7. Rezaei N1, 7
  8. Nasserinejad M1, 3
  9. Abbasikangevari M1, 4
  10. Malekpour MR1
  11. Ghamari SH1, 4
  12. Haghshenas R1, 7
  13. Koliji K5
  14. Kompani F6
  15. Farzadfar F1, 7
Show Affiliations
Authors Affiliations
  1. 1. Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Epidemiology and Biostatistics, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Biostatistics, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Science, Tehran, Iran
  4. 4. Social Determinants of Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  5. 5. Student Research Committee, Kurdistan University of Medical Sciences, Sanandaj, Iran
  6. 6. Division of Hematology and Oncology, Children’s Medical Center, Pediatrics Center of Excellence, Tehran University of Medical Sciences, Tehran, Iran
  7. 7. Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

Source: Experimental Hematology and Oncology Published:2021


Abstract

Background: Hematologic malignancies (HMs) are a heterogeneous group of cancers that comprise diverse subgroups of neoplasms. So far, despite the major epidemiologic concerns about the quality of care, limited data are available for patients with HMs. Thus, we created a novel measure—Quality of Care Index (QCI)—to appraise the quality of care in different populations. Methods: The Global Burden of Disease data from 1990 to 2017 applied in our study. We performed a principal component analysis on several secondary indices from the major primary indices, including incidence, prevalence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years (DALYs) to create the QCI, which provides an overall score of 0–100 of the quality of cancer care. We estimated the QCI for each age group on different scales and constructed the gender disparity ratio to evaluate the gender disparity of care in HMs. Results: Globally, while the overall age-standardized incidence rate of HMs increased from 1990 to 2017, the age-standardized DALYs and death rates decreased during the same period. Across countries, in 2017, Iceland (100), New Zealand (100), Australia (99.9), and China (99.3) had the highest QCI scores for non-Hodgkin lymphoma, multiple myeloma, Hodgkin lymphoma, and leukemia. Conversely, Central African Republic (11.5 and 6.1), Eritrea (9.6), and Mongolia (5.4) had the lowest QCI scores for the mentioned malignancies respectively. Overall, the QCI score was positively associated with higher sociodemographic of nations, and was negatively associated with age advancing. Conclusions: The QCI provides a robust metric to evaluate the quality of care that empowers policymakers on their responsibility to allocate the resources effectively. We found that there is an association between development status and QCI and gender equity, indicating that instant policy attention is demanded to improve health-care access. © 2021, The Author(s).
Experts (# of related papers)
Other Related Docs
10. Liquid Biopsy in Female Genital Tract (Ovarian Cancer, Endometrial Tumor, and Cervical Tumor), Liquid Biopsy in Urogenital Cancers and its Clinical Utility (2022)
14. The Role of Cxc Chemokines and Receptors in Breast Cancer, Clinical and Experimental Medicine (2025)
20. Anti-Cd20 Antibody Treatment for B-Cell Malignancies, Resistance to Anti-CD20 Antibodies and approaches for their Reversal: Volume 2 (2023)
22. Immunotherapy of Gastric and Esophageal Cancers, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
36. Tumor Immunology, Clinical Immunology (2022)